Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
14
×
gene therapy
14
×
life sciences
national blog main
national top stories
new york top stories
14
×
boston blog main
boston top stories
national
new york blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
biotech
novartis
deals
duchenne muscular dystrophy
spinal muscular atrophy
astrazeneca
biogen
cancer immunotherapy
celgene
eli lilly
europe top stories
What
bio
roundup
cancer
fda
drugs
ipo
new
therapy
week
ahead
amid
bombast
caught
congress
corner
coronavirus
crispr
days
debate
democrats
develop
discussion
drug
efforts
gene
meso’s
miss
moves
news
pandemic
past
patients
pfizer’s
pharma
presidential
promise
response
tuesday’s
vaccine
viewers
Language
unset
Current search:
fda
×
" new york top stories "
×
" gene therapy "
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More